Ningxia Zhongning Lycium barbarum (Tianren) Academician Workstation
宁夏中宁枸杞（天仁）院士工作站
Members of the academician workstation are: So Kwok-Fai, academician of the Chinese Academy of Sciences, with research interest on central nerve regeneration and repair, mental illness, and translation of Lycium barbarum substances for clinical applications; Professor Lv Long, and Jiang Yan（Engineer）, of Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences; Professor Wang Ying, South China Botanical Garden, Chinese Academy of Sciences; Professor Zhao Bing, Institute of Process Engineering, Chinese Academy of Sciences; Professor Shi Yu, Charlotte Medical University, Germany; Professor Gao Hao; Associate Professor Zhang Li, and Associate Professor Xiao Jia, Jinan University; Professor Ma Wenping, Northern University for Nationalities, etc.
院士工作站引进院士1名，系中国科学院苏国辉院士，主要从事中枢神经再生与修复、精神疾病、枸杞功效物质的基础-临床转化方面研究、中国科学院上海有机化学研究所吕龙研究员、江艳工程师；中国科学院华南植物园王瑛研究员；中国科学院过程工程研究所赵兵研究员；德国夏洛蒂医科大学时宇教授；暨南大学高昊教授、张力副教授、肖佳副教授；北方民族大学马文平教授等。
Ningxia Zhongning Lycium barbarum (Tianren) Academician Workstation
Current research projects related to Lycium barbarum glycopeptide at the Academician Workstation:
目前，院士工作站开展的枸杞糖肽相关研究项目：
1. We have cooperated with Hunan Aier Ophthalmology Group, Guangzhou Sun Yat sen University ophthalmology center, Liaoning Xingqi Ophthalmology Group, etc. to carry out the application research of Lycium barbarum glycopeptide in the field of treating eye diseases. The relevant data has been released in the fourth Lycium barbarum exposition, which initially reveals the mechanism of Lycium barbarum glycopeptide in the field of treating eye diseases. We have published 2 SCI papers, 4 master's degree papers, and applied for 3 domestic invention patents. At present, it has entered the development stage of eye drops, eye biopharmaceutical preparations and other products.
1.与湖南爱尔眼科集团、广州中山大学眼科中心、辽宁兴齐眼药集团等合作开展枸杞糖肽在治疗眼科疾病领域的应用研究，相关数据已在第四届枸杞博览会发布，初步揭示了枸杞糖肽在治疗眼科疾病领域的作用机理，发表SCI论文2片，硕士学位论文4篇，申请国内发明专利3项。目前已进入开发眼药水、眼药生物制药制剂等产品的开发阶段。
Signing of scientific and technological achievements
2.t cooperated with Jinan University and Guangzhou brain hospital to carry out the application research of Lycium barbarum glycopeptide in alleviating depression. In the same year, it was registered on the clinical trials website of the United States. Three animal experiments and clinical experiments on depression patients and high-risk groups have been carried out. Two SCI papers, one master's thesis and three domestic invention patents have been published. The preliminary experimental data have been released at the 4th Lycium barbarum exposition.
2.与暨南大学、广州市脑科医院合作开展枸杞糖肽缓解抑郁症方面的应用研究，同年，在美国Clinical Trials临床实验网站注册。现已进行了三项动物实验，和抑郁症患者及高危人群的临床实验，共发表SCI论文2篇，硕士学位论文1篇，申请国内发明专利3项。初步实验数据已在第四届枸杞博览会发布。
Release of scientific and technological achievements
3.Ningxia's "Thirteenth Five-Year Plan" major research and development project "Major basic research on the efficacy of Lycium barbarum and research and development of functional products", is led by 5 academicians: Wang Zhizhen, Chen Kaixian, Chen Runsheng, So Kwok-Fai, and Tong Xiaolin. The project has reported ten achievements, among these, three products using Lycium barbarum glycopeptide as key ingredient are successfully developed, and produced by Ningxia Tianren Goji Biotechnology.
3. 宁夏回族自治区“十三五”规划重大研发项目《枸杞功效的重大基础研究及功能产品研发》，由王志珍、陈凯先、陈润生、苏国辉、仝小林等5名院士领衔开展，此项目已发布十项成果，其中三项以枸杞糖肽为配方因子的产品，由宁夏天仁枸杞生物科技股份有限公司转化生产。
Scientific and technological achievements and products
4.Collaborating projects with Ningxia Medical University General Hospital, Harvard Medical School Genetic Engineering Institute, Queensland University, Jinan University, Tongji University, Institute of Genetics, Chinese Academy of Sciences, Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.. With the establishment of the "Ningxia Key Laboratory of Stem Cell and Regenerative Medicine" granted by Ningxia Government, it provides a very good platform for more research work and funding.
4.与宁夏医科大学总医院、哈佛大学医学院基因工程研究所、澳大利亚昆士兰大学、暨南大学、同济大学、中国科学院遗传所、山东省齐鲁细胞治疗工程技术有限公司等合作项目。宁夏回族自治区批准成立“宁夏干细胞与再生医学重点实验室”。这提供了一个非常好的平台促进科研工作和争取研究经费。
Ningxia Key Laboratory of Stem Cell and Regenerative Medicine work conference
5. Collaboration with Sichuan Provincial People's Hospital on "Application Research of Lycium barbarum Glycopeptide in Oral Cavity".
5.与四川省人民医院合作《枸杞糖肽在口腔中的应用研究》。
6. Participates in the 2018, Ningxia's key research and development plan project "The construction of a whole-process quality control system and health product development of Lycium barbarum based on Chinese medicine standardization" for product development.
6.于2018年宁夏回族自治区重点研发计划项目《基于中药标准化的枸杞全程质控体系建设及健康产品开发》参与产品开发。
7.The research results of Lycium barbarum glycopeptide (lbgp) for neuroprotection and depression intervention were published in nature focal point in October 2021. Published the research topic of Lycium barbarum in Science Bulletin.
7.枸杞糖肽（LbGp）用于神经保护、干预抑郁等研究成果刊发于2021年10月《Nature》Focal Point。出版《科学通报》枸杞研究专题。
8.Cooperated with Professor He Rongrong of the school of pharmacy of Jinan University to carry out the experiment of Lycium barbarum glycopeptide for Parkinson's disease, completed the preliminary pharmacological experiment in January 2022, is conducting the second phase of pharmacological experiment, applied for one domestic patent, and carried out international patent registration. This research result was released at the 2022 Chinese wolfberry Industry Expo.
8.与暨南大学药学院何蓉蓉教授合作开展枸杞糖肽用于帕金森实验，2022年1月完成初步药理实验，正在进行第2阶段药理实验，申请国内专利1个，开展国际了专利注册。此项研究成果，在2022年枸杞产业博览会上发布。
9.He carried out research with Professor Le Weidong of Sichuan people's Hospital on the therapeutic effect and mechanism of Lycium barbarum glycopeptide on amyotrophic lateral sclerosis, published one paper in Chinese core journals, one in SCI paper review, applied for one domestic invention patent, and carried out international registration. This research result was released at the 2022 Chinese wolfberry Industry Expo.
9.与四川人民医院乐卫东教授开展研究：枸杞糖肽对肌萎缩侧索硬化的治疗作用及其机制的研究，发布中文核心期刊论文1篇，SCI论文审稿中1篇，申请国内发明专利1项，并开展国际注册。此项研究成果，在2022年枸杞产业博览会上发布。
10.Two studies were carried out with Professor Qin Meng of Beijing University of Chemical Technology: Lycium barbarum glycopeptide for novel coronavirus and Lycium barbarum glycopeptide for viral pneumonia. In June 2021, he completed the experiment, published one SCI paper, reviewed two drafts, completed two master's thesis, and applied for two domestic invention patents. This research result was released at the 2022 Chinese wolfberry Industry Expo.
10.与北京化工大学秦蒙教授开展两项研究：枸杞糖肽用于新冠病毒、枸杞糖肽用于病毒性肺炎。2021年6月完成实验，发表SCI论文1篇，审稿中2篇，硕士结业论文2篇，申请国内发明专利2项。此项研究成果，在2022年枸杞产业博览会上发布。
In 2022, he will work with Academician Su Guohui, academician Zhong Nanshan and Associate Professor Qin Meng of Beijing University of Chemical Technology in the key P3 Laboratory of respiratory diseases: Lycium barbarum glycopeptide for novel coronavirus β The mutant infects animals. The experiment has been completed and the second phase of the experiment is planned. In May of the same year, we cooperated with the Institute of infectious disease prevention and control of the Chinese Center for Disease Control and prevention to carry out research in P3 Laboratory of the Institute of infectious disease prevention and control of the Chinese Center for Disease Control and prevention: Lycium barbarum glycopeptide was used to infect cells with Omicron variant of novel coronavirus. In August of the same year, we completed the experiment, and planned to carry out phase 2 experiments and animal experiments. In September, the research "clinical application of Lycium barbarum glycopeptide in new coronavirus" was carried out. The above research results will be released to the public at an appropriate time. At present, the antiviral preparation of Lycium barbarum glycopeptide is being studied
2022年与苏国辉院士、钟南山院士、北京化工大学秦蒙副教授，在呼吸疾病重点P3实验室开展研究：枸杞糖肽用于新冠病毒β变异株感染动物，已完成实验，计划开展第2期实验。同年5月与中国疾控中心传染病预防控制所，在中国疾控中心传染病预防控制所P3实验室，开展研究：枸杞糖肽用于新冠病毒奥米克戎变异株感染细胞，8月完成实验，计划开展2期实验，动物实验。9月，开展研究：“枸杞糖肽新冠临床应用”。上述研究结果，将择机对公众发布。目前正在进行枸杞糖肽抗病毒制剂研究。
Lycium barbarum glycopeptide (LBGP), driven by the team members of Ningxia Zhongning Lycium barbarum (Tianren) academician workstation and under the continuous transformation of Ningxia Tianren Goji Biotechnology will continue to carry out research on key and common technologies and research and development of new products.
枸杞糖肽在宁夏中宁枸杞（天仁）院士工作站团队成员的推动下，在宁夏天仁枸杞生物科技股份有限公司不断的转化下，将继续开展关键性和共性技术的研究以及新产品的研发。
If you are interested in Lycium barbarum, please contact us!
诚挚欢迎对枸杞感兴趣的伙伴联系我们！
e-mail address 1:Lyciumbarbarum@vip.tom.com
e-mail address 2: Lyciumbarbarum@hotmail.com